Back
Gracell Biotechnologies
IPOGRCL.NASDAQPast

Gracell Biotechnologies

Developer of cancer immune therapy designed to treat cancer

Company website ↗
Foundation year: 2017
Profitability
+54.95%
IPO date
07/01/2021

About

Total Funding 

$185M


Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.


Number of employees

51-100


Headquarters

Suzhou, Jiangsu, China